Please login to the form below

diffuse large B-cell lymphoma

This page shows the latest diffuse large B-cell lymphoma news and features for those working in and with pharma, biotech and healthcare.

Gracell reports impressive data with one-day CAR-T for leukaemia

Kymriah is approved for B-ALL as well as diffuse large B-cell lymphoma (DLBCL) – a form of non-Hodgkin’s lymphoma – and made just over $100m in sales in the ... Meanwhile, Gilead reported $216m in first-half sales from DLBCL and another NHL variant

Latest news

Novartis’ CAR-T Kymriah scores SMC approval

The SMC approved the CAR-T therapy for use in adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), who have not responded to two or more prior ... From the testimonies given by patient groups and clinicians through our PACE
Imbruvica gains expanded use in Europe

It is also approved for use in mantle cell lymphoma (MCL) for the treatment of adult patients who have relapsed or refractory MCL. ... B-cell lymphoma.
Triplet approvals for myeloma boost Celgene in Q2

Abraxane is enjoying a sales surge thanks to its use in combination with cancer immunotherapies in indications like non-small cell lung cancer (NSCLC) and triple-negative breast cancer (TNBC), according ... CAR-T therapy liso-cel (lisocabtagene maraleucel
J&J takes option on Genmab follow-up to Darzalex

Johnson &Johnson’s longstanding alliance with Genmab has already produced one blockbuster drug for lymphoma – Darzalex – and it is now eyeing a follow-up candidate. ... Under the terms of the deal Genmab will develop HexaBody-CD38 for multiple
Roche’s Polivy gets FDA okay for lymphoma chemo-immunotherapy

First-in-class antibody drug conjugate. The FDA has approved Roche’s Polivy as part of the first chemo-immunotherapy combination for a B-cell lymphoma. ... The antibody-drug conjugate has been cleared for use alongside the chemotherapy bendamustine and

More from news
Approximately 1 fully matching, plus 73 partially matching documents found.

Latest Intelligence

European biotech: a new generation of leaders emerges

The phase 2 L-MIND study in diffuse large B-cell lymphoma (DLBCL) showed the combination of tafasitamab with Celgene’s Revlimid (lenalidomide) had an overall response rate of 60%, with ... Nevertheless, European biotech has reason to be optimistic
25 Women Leaders in UK Healthcare (part 2)

13. SORAYA BEKKALI. Gene therapy pioneer. Cell and gene therapy is definitely the most exciting development in biopharma research, promising breakthroughs and even cures for previously untreatable diseases. ... It has brought to market not one but two
Cancer immunotherapy: What's on the horizon?

antigen receptor T-cell (CAR-T) therapies from Novartis and Gilead gained regulatory approval in 2017 for acute lymphoblastic leukaemia (ALL) and diffuse large B-cell lymphoma (DLBCL) after showing remarkable ... Celgene and Juno hope to crash the party
Deal Watch January 2018

pivotal trial for relapsed and/or refractory diffuse large B-cell lymphoma (DLBCL). According to Celgene's press release, regulatory approval for JCAR017 in the US is anticipated in 2019 with ... DLBCL = diffuse large B-cell lymphoma. BTK = Bruton's
Pharma deals in April 2015

MEDI4736 is an immune checkpoint inhibitor which is targeted against programmed cell death (PD-L1). ... its SAR3419, an antibody-drug conjugate designed to treat diffuse large B-cell lymphoma (DLBCL) and other blood cancers.

More from intelligence
Approximately 0 fully matching, plus 7 partially matching documents found.

Latest from PMHub

Highlights in haematologic malignancy from ASH 2018

refractory diffuse large B-cell lymphoma. ... Other abstracts reported on CAR T-cell therapies for multiple myeloma directed against the B-cell maturation antigen (BCMA).

More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.